CORRECTION article

Front. Oncol., 06 December 2024

Sec. Pharmacology of Anti-Cancer Drugs

Volume 14 - 2024 | https://doi.org/10.3389/fonc.2024.1532291

Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells

  • 1. Department of Medicine and Surgery, University of Parma, Parma, Italy

  • 2. Department of Occupational and Environmental Medicine, Epidemiology and Hygiene, INAIL - Italian Workers’ Compensation Authority, Rome, Italy

  • 3. Paediatric Hematology Oncology Unit, University Hospital of Parma, Parma, Italy

  • 4. Unit of Infectious Diseases and Hepatology, University Hospital of Parma, Parma, Italy

In the published article, there was an error in Figures 2B and 3D as published. Two representative images of colony formation were unintentionally inserted twice during the figure assembly for the manuscript preparation. The images of HepG2 cells shown in Figure 3D were inserted by mistake in Figure 2B (panel HepG2 cells). The images of HUH7 shown in Figure 2B were inserted by mistake in Figure 3D (panel SNU398 cells). The corrected Figure 2B and Figure 3D and their caption appear below.

Figure 2

Figure 3

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

hepatocarcinoma (HCC), CDK4/6 inhibition, abemaciclib, lenvatinib, senescence

Citation

Digiacomo G, Fumarola C, La Monica S, Bonelli M, Cavazzoni A, Galetti M, Terenziani R, Eltayeb K, Volta F, Zoppi S, Bertolini P, Missale G, Alfieri R and Petronini PG (2024) Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells. Front. Oncol. 14:1532291. doi: 10.3389/fonc.2024.1532291

Received

21 November 2024

Accepted

26 November 2024

Published

06 December 2024

Volume

14 - 2024

Edited and reviewed by

Tong-Chuan He, University of Chicago Medicine, United States

Updates

Copyright

*Correspondence: Silvia La Monica, ; Andrea Cavazzoni,

†These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics